Breaking News
April 23, 2019 - Research shows mindful body awareness training helps women recover from drug addiction
April 23, 2019 - Researchers are developing brand-new method to cure brain tumors
April 23, 2019 - Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium/Hydrochlorothiazide Tablets, USP
April 23, 2019 - First case of person without the protein needed to transport vitamin D identified
April 23, 2019 - Precision-guided anticancer nanoparticles help enhance treatment of peritoneal tumors
April 23, 2019 - Smoking cessation during pregnancy associated with reduced risk of preterm birth
April 23, 2019 - Researchers discover why women get autoimmune diseases far more often than men
April 23, 2019 - New Medicare reimbursement rules provide some relief to safety-net hospitals
April 23, 2019 - Sensory Sensitivity Tied to Constipation in Young Children
April 23, 2019 - More than half of internal medicine graduates choosing primary care
April 22, 2019 - Researchers discover good news for fish populations living on bleached coral reefs
April 22, 2019 - Plant-based diets associated with lower risk of heart failure
April 22, 2019 - Food Allergies Can Strike at Any Age
April 22, 2019 - Cerebro-facio-thoracic dysplasia – Genetics Home Reference
April 22, 2019 - Poverty leaves a mark on our genes
April 22, 2019 - Countdown to Big Data in Precision Health: When industry and academia converge
April 22, 2019 - The U.S government may account for up to $37.8 billion due to opioid epidemic
April 22, 2019 - Improving ACA’s Insurance Coverage Provisions will lead to better care for patients
April 22, 2019 - Study identifies possible therapeutic effects of curcumin on stomach cancer
April 22, 2019 - Hyaline fibromatosis syndrome – Genetics Home Reference
April 22, 2019 - Scientists use CRISPR for possible ‘bubble boy’ therapy
April 22, 2019 - Hematologist (and a mom, singer, actress and much more) stands up for diversity
April 22, 2019 - Novel AI voice tool can help diagnose PTSD
April 22, 2019 - Overlooked part of cell’s internal machinery may hold key to treating acute myeloid leukemia
April 22, 2019 - Nursing, medical, and dental students train together to improve pediatric oral health
April 22, 2019 - Soft bedding responsible for majority of sleep-related infant deaths, study reveals
April 22, 2019 - Study finds worse health-related quality of life among transgender adults
April 22, 2019 - MIT scientists reverse some behavioral symptoms of rare neurodevelopmental disorder
April 22, 2019 - Scientists find new therapy target for drug-induced liver failure
April 22, 2019 - Opioid dose variability could lead to increased risk of overdose, study suggests
April 22, 2019 - Newly developed model predicts salmonella outbreaks several months in advance
April 22, 2019 - Deep-learning model better predicts survival outcomes for lung cancer
April 22, 2019 - One in Three U.S. Adults Aged 35 to 44 May Have Drinking Problem
April 22, 2019 - Why the measles virus is so contagious
April 22, 2019 - Magnet ‘Zap’ to the Brain Might Jumpstart Aging Memory
April 22, 2019 - Immune response to gut microbes may be early indicator of type 1 diabetes
April 22, 2019 - Destination Limbo: Health Suffers Among Asylum Seekers In Crowded Border Shelter
April 22, 2019 - Research shows how dopamine contributes to sex differences in worms
April 22, 2019 - Marijuana users weigh less compared to non-users
April 22, 2019 - Research uncovers critical RNA processing aberrations in ALS and FTD
April 22, 2019 - Many cancer patients use marijuana and prescription opioids, study reveals
April 22, 2019 - Frailty may up fracture risk in patients with type 2 diabetes
April 22, 2019 - Study provides new insight into how obesity, insulin resistance can affect cognition
April 22, 2019 - Study seeks to better understand the genetic causes for hypospadias
April 22, 2019 - FDA grants approval of first generic naloxone nasal spray to treat opioid overdose
April 22, 2019 - FDA authorizes marketing of first medical device to treat ADHD
April 22, 2019 - Vanderbilt researchers to develop and test ‘safe harbor’ standards of care
April 22, 2019 - You’re probably brushing your teeth wrong – here are four tips for better dental health
April 22, 2019 - Pharmacy closures contribute to medication non-adherence among heart patients
April 22, 2019 - Using Edge AI technology to observe behavior of cattle
April 22, 2019 - Bacteria play a role in the development of stomach ulcers in pigs
April 22, 2019 - Hand Hygiene Compliance Poor in Task Transitions
April 22, 2019 - smoking could harm your baby
April 22, 2019 - Scientists identify rare, paradoxical response to antiretroviral therapy
April 21, 2019 - More TV, Tablets, More Attention Issues at Age 5
April 21, 2019 - Drug reduces risk of kidney failure in people with diabetes, study finds
April 21, 2019 - New research identifies novel link between antibiotic resistance and climate change
April 21, 2019 - Simple intervention can provide lasting protection for teens against junk food marketing
April 21, 2019 - The protein p38-gamma identified as a new therapeutic target in liver cancer
April 21, 2019 - Novel system enables researchers to study bacteria within mini-tissues in a dish
April 21, 2019 - Discovery of oral cancer biomarkers could save thousands of lives
April 21, 2019 - Geneva Exhibition committee gives gold medals to two medications developed by Kazan
April 21, 2019 - Scientists aim to minimize or eliminate hair loss during cancer treatment
April 21, 2019 - WiFi interacts with signaling pathways in the human brain
April 21, 2019 - Stroke Hospitalizations Down in Black, White Medicare Enrollees
April 21, 2019 - First common risk genes discovered for autism
April 21, 2019 - Researchers map auditory sensory system of the mouse brain
April 21, 2019 - Scientists Bring Pig’s Brain, Dead 4 Hours, Back to ‘Cellular Activity’
April 21, 2019 - Virtual reality a promising tool for reducing fears and phobia in autism
April 21, 2019 - New analysis lists out opportunities for U.S. medical schools to advance population health
April 21, 2019 - More sleep may help teens with ADHD focus and organize
April 21, 2019 - Breakthrough antibody treatment suppresses HIV without antivirals
April 21, 2019 - AveXis Data Reinforce Effectiveness of Zolgensma in Treating Spinal Muscular Atrophy (SMA) Type 1
April 21, 2019 - Is your hand pain arthritis, carpal tunnel or something else?
April 21, 2019 - Measles outbreaks may become more frequent if vaccination rates continue to decline
April 21, 2019 - Researchers succeed in accelerating process of creating 3D images
April 21, 2019 - Tiny worm mimics key genetic risk for Alzheimer’s
April 21, 2019 - Angry dreams explained by brain waves
April 20, 2019 - Parenteral Antimicrobial Tx at Home Burdens Children’s Caregivers
April 20, 2019 - Diabetes treatment may keep dementia, Alzheimer’s at bay
Breast cancer survival could be extended with two new drug combinations

Breast cancer survival could be extended with two new drug combinations

image_pdfDownload PDFimage_print

Study 1

A new study has shown that a combination of drugs palbociclib, along with hormone therapy can significantly increase the survival among women with advanced breast cancer.

The new study titled, “Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer,” was published in the latest issue of the New England Journal of Medicine and the results of the PALOMA-3 trial were also presented at the European Society of Medical Oncology congress in Munich, Germany. The researchers from Institute of Cancer Research and Royal Marsden NHS Foundation Trust, found that women with advanced breast cancer treated with this combination lived for seven months longer than those who were treated with hormonal therapy alone. Among women who had earlier responded favourably to hormone therapy, the average survival when palbociclib and hormone therapy was administered together was around 10 months.

Dividing breast cancer cell. Image Credit: royaltystockphoto.com / Shutterstock

Dividing breast cancer cell. Image Credit: royaltystockphoto.com / Shutterstock

Study leader, Professor Nick Turner of the Institute of Cancer Research said, “These results indicate that we can now offer women with incurable breast cancer some precious extra survival time before their condition worsens. It is very encouraging.” The study involved a total of 521 women with advanced, hormone-sensitive breast cancer. The researchers attempted to see if the combination therapy worked better than conventional chemotherapy.

Results of the study funded by palbociclib’s manufacturer Pfizer, showed that women who were given a combination therapy survived for an average of 34.9 months. This is an average of 6.9 months longer than women treated only with hormonal therapy. Three years after the study enrolment 49.6 percent of the participants who had received the combination therapy were still alive compared to 40.8 percent of the participants who had received only hormone therapy.

Authors concluded in their study, “Among patients with hormone-receptor–positive, HER2-negative advanced breast cancer who had sensitivity to previous endocrine therapy, treatment with palbociclib–fulvestrant resulted in longer overall survival than treatment with placebo–fulvestrant. The differences in overall survival in the entire trial group were not significant.”

Study 2

Yet another combination of an immunotherapy drug atezolizumab with standard chemotherapy was found to prolong life of patients with advanced triple-negative breast cancers.

This study titled, “Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer,” was led by Professor Peter Schmid, clinical director of breast cancer at St Bartholomew’s Hospital and professor of cancer medicine at Queen Mary University of London and the results of the study were published in the New England Journal of Medicine. According to Schmid this study is a “massive step forward” and could soon “lead to a cure in some patients and may apply in the treatment of other forms of breast cancers in the future.”

The researchers explained that the chemotherapy made the tumour vulnerable and the immunotherapy then targeted the breast cancer cells. In this trial 451 patients were included in two groups – one to receive atezolizumab plus nab-paclitaxel or placebo plus nab-paclitaxel. The patients all had untreated metastatic triple-negative breast cancer. The patients were all followed up for an average 12.9 months.

Results showed that progression-free survival was 7.2 months with atezolizumab plus nab-paclitaxel and it was 5.5 months with placebo plus nab-paclitaxel. Median overall survival was 21.3 months with the combination therapy and it was 17.6 months with paclitaxel along with placebo. Side effects were seen among 15.9 percent patients on the combination and 8.2 percent on paclitaxel alone. At 25 months after the study 60 percent of the combination group were still alive. The combination treatment was found to reduce the risk of the cancer progress by up to 40 percent.

According to Professor Schmid, “Triple-negative breast cancer is an aggressive form of breast cancer. It is particularly tragic that those affected are often young. I’m thrilled that by using a combination of immunotherapy and chemotherapy we are able to significantly extend lives compared to the standard treatment of chemotherapy alone.”

Source:

https://www.nejm.org/doi/full/10.1056/NEJMoa1810527 and https://www.nejm.org/doi/full/10.1056/NEJMoa1809615

Tagged with:

About author

Related Articles